9 July 2024 Pan-European court hands down second infringement decision | Revokes patent Europe-wide after counterclaim | ...

DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors ...

The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap ...

DexCom Inc (NASDAQ:DXCM) shares up more than 2% following updated guidelines by the American Diabetes Association (ADA), which now recommend using continuous glucose monitors (CGMs) for some adults ...

SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third ...

Tandem Diabetes Care has received authorization of sale by Health Canada, paving the way for in-warranty t:slim X2 insulin pump users to be full compatibility with both the Dexcom G7 and Dexcom G6 ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...